Overview and Scope
Pompe disease is a genetic condition in which a complex sugar called glycogen accumulates in the body’s cells. The situation is caused by a lack of an enzyme known as acid alfa glucosidase (GAA), which breaks down complex carbohydrates in the body.
Sizing and Forecast
The pompe disease market size has grown steadily in recent years. It will grow from $1.66 billion in 2023 to $1.73 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increased awareness and diagnosis, orphan drug designation and incentives, global collaborations and research initiatives, patient advocacy and support groups..
The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to continued research and development, expansion of newborn screening programs, advancements in gene therapy, increasing global investment in rare diseases, patient-centric drug development, expansion of clinical trials and research initiatives, market emphasis on personalized medicine approaches. Major trends in the forecast period include product innovation, technological advancements, implementation of patient support programs, growing adoption of telemedicine for patient management, collaborations for expanded access programs..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report
Segmentation & Regional Insights
The pompe disease market covered in this report is segmented –
1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types
2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis
3) By Route of Administration: Oral, Parenteral, Other routes of administrations
4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies
5) By End Users: Hospitals / Clinics, Pharmaceuticals, Researchers, Other End-Users
North America was the largest region in the pompe disease market in 2023. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11906&type=smp
Major Driver Impacting Market Growth
The increase in the prevalence of pompe disease is expected to propel the growth of the pompe disease market. Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare genetic disorder characterized by the build-up of glycogen (a complex sugar molecule) in various body tissues, particularly in muscles and organs. Treatments for pompe disease include protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. A rise in pompe disease cases will contribute to the growth of the pompe disease market. For instance, in June 2022, according to the European Medicines Agency Highlights, a Europe-based intergovernmental organization, there are roughly 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset persons in Europe with mutations that potentially cause Pompe disease based on the maximum birth incidence of 11.6 per 100,000. Therefore, the increase in the prevalence of pompe disease is driving the growth of the pompe disease market.
Key Industry Players
Major companies operating in the pompe disease market report are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Becton, Dickinson and Company, Astellas Pharma Inc., BioMérieux SA, BioMarin Pharmaceutical Inc., Nova Biomedical Corporation, Instrumentation Laboratory Company, Amicus Therapeutics Inc., Sekisui Diagnostics LLC, Spark Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Avrobio Inc., EKF Diagnostics Holdings PLC, Trinity Biotech PLC, Chembio Diagnostics Inc., Audentes Therapeutics Inc., Rougine Darou, Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC
The pompe disease market report table of contents includes:
1. Executive Summary
2. Pompe Disease Market Characteristics
3. Pompe Disease Market Trends And Strategies
4. Pompe Disease Market – Macro Economic Scenario
5. Global Pompe Disease Market Size and Growth
.
.
.
31. Pompe Disease Market Other Major And Innovative Companies
32. Global Pompe Disease Market Competitive Benchmarking
33. Global Pompe Disease Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Pompe Disease Market
35. Pompe Disease Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
